Literature DB >> 12750294

Transactivation of vimentin by beta-catenin in human breast cancer cells.

Christine Gilles1, Myriam Polette, Mélanie Mestdagt, Béatrice Nawrocki-Raby, Philippe Ruggeri, Philippe Birembaut, Jean-Michel Foidart.   

Abstract

The cytoplasmic and nuclear redistribution of beta-catenin and the de novo expression of vimentin are frequently involved in the epithelial-to-mesenchymal transition associated with increased invasive/migratory properties of epithelial cells. Because beta-catenin can act as a coactivator of transcription through its binding to the T-cell factor (TCF)/lymphoid enhancer factor 1 transcription factor family, we have explored the possibility that beta-catenin/TCF could directly transactivate vimentin. We first compared vimentin expression in relation with the localization of beta-catenin in eight breast cancer cell lines displaying various degrees of invasiveness and in a model of cell migration using human mammary MCF10A cells. We could thus show a cytoplasmic and/or nuclear distribution of beta-catenin in invasive/migratory cells expressing vimentin, but not in noninvasive/stationary vimentin-negative cell lines. In addition, the human vimentin promoter was found to be up-regulated by beta-catenin and TCF-4 cotransfection. Varying with the cellular background, a diminution of this up-regulation was observed when the putative beta-catenin/TCF binding site of the vimentin promoter was mutated. Our results therefore demonstrate that the vimentin promoter is a target of the beta-catenin/TCF pathway and strongly suggest an implication of this regulation in epithelial cell migration/invasion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750294

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  139 in total

Review 1.  Vimentin in cancer and its potential as a molecular target for cancer therapy.

Authors:  Arun Satelli; Shulin Li
Journal:  Cell Mol Life Sci       Date:  2011-06-03       Impact factor: 9.261

2.  Crosstalk between SOXB1 proteins and WNT/β-catenin signaling in NT2/D1 cells.

Authors:  Marija Mojsin; Vladanka Topalovic; Jelena Marjanovic Vicentic; Marija Schwirtlich; Danijela Stanisavljevic; Danijela Drakulic; Milena Stevanovic
Journal:  Histochem Cell Biol       Date:  2015-08-04       Impact factor: 4.304

Review 3.  Melatonin: an inhibitor of breast cancer.

Authors:  Steven M Hill; Victoria P Belancio; Robert T Dauchy; Shulin Xiang; Samantha Brimer; Lulu Mao; Adam Hauch; Peter W Lundberg; Whitney Summers; Lin Yuan; Tripp Frasch; David E Blask
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

4.  Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer.

Authors:  Yelena Mironchik; Paul T Winnard; Farhad Vesuna; Yoshinori Kato; Flonne Wildes; Arvind P Pathak; Scott Kominsky; Dmitri Artemov; Zaver Bhujwalla; Paul Van Diest; Horst Burger; Carlotta Glackin; Venu Raman
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

5.  ZEB1 and TCF4 reciprocally modulate their transcriptional activities to regulate Wnt target gene expression.

Authors:  E Sánchez-Tilló; O de Barrios; E Valls; D S Darling; A Castells; A Postigo
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

6.  Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner.

Authors:  Y Liu; G Wang; Y Yang; Z Mei; Z Liang; A Cui; T Wu; C-Y Liu; L Cui
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

7.  Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: role for beta-catenin.

Authors:  András Masszi; Lingzhi Fan; László Rosivall; Christopher A McCulloch; Ori D Rotstein; István Mucsi; András Kapus
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 8.  Circulating tumor cells in sarcomas: a brief review.

Authors:  Le Chang; Greg Asatrian; Sarah M Dry; Aaron W James
Journal:  Med Oncol       Date:  2014-12-10       Impact factor: 3.064

Review 9.  mTOR inhibitors and renal allograft: Yin and Yang.

Authors:  Gianluigi Zaza; Simona Granata; Paola Tomei; Valentina Masola; Giovanni Gambaro; Antonio Lupo
Journal:  J Nephrol       Date:  2014-05-08       Impact factor: 3.902

10.  MAD2B, a novel TCF4-binding protein, modulates TCF4-mediated epithelial-mesenchymal transdifferentiation.

Authors:  Chun-Fu Hong; Yu-Ting Chou; Young-Sun Lin; Cheng-Wen Wu
Journal:  J Biol Chem       Date:  2009-05-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.